Preparation, characterization, and in vivo pharmacokinetics of thermosensitive in situ nasal gel of donepezil hydrochloride

1. C. A. Lane, J. Hardy and J. M. Schott, Alzheimer’s disease, Eur. J. Neurol. 25 (2018) 59–70; https://doi.org/10.1111/ene.1343910.1111/ene.1343928872215Search in Google Scholar

2. L. A. Craig, N. S. Hong and R. J. McDonald, Revisiting the cholinergic hypothesis in the development of Alzheimer’s disease, Neurosci. Biobehav. Rev.35 (2011) 1397–1409; https://doi.org/10.1016/j.neubiorev.2011.03.00110.1016/j.neubiorev.2011.03.00121392524Search in Google Scholar

3. T. Maurice, Protection by sigma-1 receptor agonists is synergic with donepezil, but not with memantine, in a mouse model of amyloid-induced memory impairments, Behav. Brain Res. 296 (2016) 270–278; https://doi.org/10.1016/j.bbr.2015.09.02010.1016/j.bbr.2015.09.02026386305Search in Google Scholar

4. K. Meguro, M. Kasai, M. Meguro, H. Ishii and S. Yamaguchi, Donepezil and life expectancy in Alzheimer’s disease: A retrospective analysis in the Tajiri Project, BMC Neurol. 14 (2014) 83; https://doi.org/10.1186/1471-2377-14-8310.1186/1471-2377-14-83399719524720852Search in Google Scholar

5. E. Garcia-Garcia, K. Andrieux, S. Gil and P. Couvreur, Colloidal carriers and blood-brain barrier (BBB) translocation: a way to deliver drugs to the brain? Int. J. Pharm. 298 (2005) 274–292; https://doi.org/10.1016/j.ijpharm.2005.03.03110.1016/j.ijpharm.2005.03.03115896933Search in Google Scholar

6. C. V. Pardeshi and V. S. Belgamwar, Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood-brain barrier: an excellent platform for brain targeting, Expert Opin. Drug Del. 10 (2013) 957–972; https://doi.org/10.1517/17425247.2013.79088710.1517/17425247.2013.79088723586809Search in Google Scholar

7. M. Agrawal, S. Saraf, S. Saraf, S. G. Antimisiaris, M. B. Chougule, S. A. Shoyele and A. Alexander, Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs, J. Control. Release281 (2018) 139–177; https://doi.org/10.1016/j.jconrel.2018.05.01110.1016/j.jconrel.2018.05.01129772289Search in Google Scholar

8. C. Christodoulou, P. Melville, W. F. Scherl, W. S. Macallister, L. E. Elkins and L. B. Krupp, Effects of donepezil on memory and cognition in multiple sclerosis, J. Neurol. Sci.245 (2006) 127–136; https://doi.org/10.1016/j.jns.2005.08.02110.1016/j.jns.2005.08.02116626752Search in Google Scholar

9. L. C. Espinoza, M. Vacacela, B. Clares, M. L. Garcia, M. J. Fabrega and A. C. Calpena, Development of a nasal donepezil-loaded microemulsion for the treatment of Alzheimer’s disease: in vitro and ex vivo characterization, CNS Neuro. Disord. Drug Targets17 (2018) 43–53; https://doi.org/10.2174/187152731766618010412234710.2174/187152731766618010412234729299992Search in Google Scholar

10. Bhavna, Shadab Md, M. Ali, R. Ali, A. Bhatnagar, S. Baboota and J. Ali, Donepezil nanosuspension intended for nose to brain targeting: In vitro and in vivo safety evaluation, Int. J. Biol. Macromol. 67 (2014) 418–425; https://doi.org/10.1016/j.ijbiomac.2014.03.02210.1016/j.ijbiomac.2014.03.02224705169Search in Google Scholar

11. A. K. Al Asmari, Z. Ullah, M. Tariq and A. Fatani, Preparation, characterization, and in vivo evaluation of intranasally administered liposomal formulation of donepezil, Drug Des. Devel. Ther. 10 (2016) 205–215; https://doi.org/10.2147/DDDT.S9393710.2147/DDDT.S93937Search in Google Scholar

12. S. Al Harthi, S. E. Alavi, M. A. Radwan, M. M. El Khatib and I. A. Al Sarra, Nasal delivery of donepezil HCl-loaded hydrogels for the treatment of Alzheimer’s disease, Sci. Rep. 9 (2019) 9563; https://doi.org/10.1038/s41598-019-46032-y10.1038/s41598-019-46032-ySearch in Google Scholar

13. C. Karavasili and D. G. Fatouros, Smart materials: in situ gel-forming systems for nasal delivery, Drug Discov. Today21 (2016) 157–166; https://doi.org/10.1016/j.drudis.2015.10.01610.1016/j.drudis.2015.10.016Search in Google Scholar

14. J. C. Gilbert, J. Hadgraft, A. Bye and L. G. Brookes, Drug release from Pluronic F-127 gels, Int. J. Pharm. 32 (1986) 223–228; https://doi.org/10.1016/0378-5173(86)90182-110.1016/0378-5173(86)90182-1Search in Google Scholar

15. L. E. Jabarian, M. R. Rouini, F. Atyabi, A. Foroumadi, S. M. Nassiri and R. Dinarvand, In vitro and in vivo evaluation of an in situ gel forming system for the delivery of PEGylated octreotide, Eur. J. Pharm. Sci. 48 (2013) 87–96; https://doi.org/10.1016/j.ejps.2012.09.01710.1016/j.ejps.2012.09.017Search in Google Scholar

16. Y. C. Li, H. Xin and L. Gao, To establish an HPLC-ESI-SIM method for the determination of done-pezil in human plasma, Chin. J. Aesthetic Med.21 (2012) 24–26; https://doi.org/10.15909/j.cnki.cn61-1347/r.2012.16.451Search in Google Scholar

17. M. Valis, J. Masopust, O. Vysata, J. Hort, R. Dolezal, J. Tomek, J. Misik, K. Kuca and J. Z. Karasova, Concentration of donepezil in the cerebrospinal fluid of AD Patients: Evaluation of dosage sufficiency in standard treatment strategy, Neurotox. Res. 31 (2017) 162–168; https://doi.org/10.1007/s12640-016-9672-y10.1007/s12640-016-9672-ySearch in Google Scholar

18. U. C. Galgatte, A. B. Kumbhar and P. D. Chaudhari, Development of in situ gel for nasal delivery: design, optimization, in vitro and in vivo evaluation, Drug Deliv.21 (2014) 62–73; https://doi.org/10.3109/10717544.2013.84977810.3109/10717544.2013.849778Search in Google Scholar

19. H. M. Fan, Z. X. Cong and F. G. Gu, Preparation and in vitro properties of thermosensitive in situ nasal gel of donepezil hydrochloride, Centr. South Pharm. 16 (2018) 1194–1199; https://doi.org/10.7539/j.issn.1672-2981.2018.09.003 (in Chinese only)Search in Google Scholar

20. Q. Wang, Z. Zuo, C. K. C. Cheung and S. S. Y. Leung, Updates on thermosensitive hydrogel for nasal, ocular and cutaneous delivery, Int. J. Pharm.559 (2019) 86–101; https://doi.org/10.1016/j.ijpharm.2019.01.03010.1016/j.ijpharm.2019.01.030Search in Google Scholar

21. C. R. Behl, H. K. Pimplaskar, A. P. Sileno, J. deMeireles and V. D. Romeo, Effects of physicochemical properties and other factors on systemic nasal drug delivery, Adv. Drug Deliv. Rev. 29 (1998) 89–116; https://doi.org/10.1016/s0169-409x(97)00063-x10.1016/S0169-409X(97)00063-XSearch in Google Scholar